The proposed lawsuit alleges Erasca misled investors about comparative claims for its lead oncology candidate before disclosing patent and trade secret accusations, limited cross-study comparisons and a patient death.
Berger Montague PC said it has filed a class action lawsuit against Erasca, Inc. on behalf of investors who bought or acquired the company's common stock between January 14, 2025 and April 26, 2026. Investors seeking appointment as lead plaintiff have until August 10, 2026. The complaint centers on Erasca's statements about ERAS-0015, a pan-RAS molecular glue being developed for RAS-mutated solid tumors. The suit alleges the company repeatedly promoted the drug candidate as a potential "best-in-class" therapy and cited supposedly superior preclinical results versus Revolution Medicines' RMC-6236 without disclosing that the comparisons were allegedly improper and exposed Erasca to patent infringement and trade secret disputes. Berger Montague said those issues began to surface on April 27, 2026, when Erasca disclosed that Revolution Medicines had accused it of patent infringement and trade secret misappropriation and of making deceptive comparative statements about ERAS-0015. Later that day, Erasca also released preliminary clinical data that included a patient death and said comparisons between ERAS-0015 and competing therapies were based on limited cross-study analyses rather than head-to-head clinical trials. Erasca shares then fell more than 45%, or $9.90 per share, according to the release.